Campus

Order material

Logg Inn
Registrering

Terapiområder

Luftveiene
Astma
Nesepolyper (CRSwNP)

Neurologi
Multippel sklerose

Transplantasjon
cGVHD (chronic Graft-versus-Host Disease)

Onkologi
Myelomatose

Sjelden sykdom
Fabry
Pompe
Gaucher

Dermatologi
Atopisk Dermatitt: Behandling
Prurigo Nodularis: Innsikt

Vaksiner
Influensavaksiner: Effektivitet

Hematologi
Ervervet Trombotisk Trombocytopenisk Purpura

Diabetes
Type 2 Diabetes
Type 1 Diabetes

Utdannelse

Dermatologi
Prurigo Nodularis
Atopisk Dermatitt

Diabetes
Type 1 Diabetes: Forskning
Type 2 Diabetes

Kardiologi
Dyslipidemi

Luftveiene
Astma
Nesepolyper (CRSwNP)
Chronic Obstructive Pulmonary Disease (COPD)

Neurologi
Multippel sklerose

Hematologi
Ervervet Trombotisk Trombocytopenisk Purpura

Sjelden sykdom
Fabry
Gaucher

Vaksiner
Influenza

Onkologi
Myelomatose

Artikler

Dermatologi
Atopisk Dermatitt
Prurigo Nodularis: Behandlingsvalg

Hematologi
Ervervet Trombotisk Trombocytopenisk Purpura

Diabetes
Type 2 Diabetes: Behandling og Forskning
Type 1 Diabetes: Artikler og Behandling

Kardiologi
Dyslipidemi

Sjelden sykdom
Fabry
Gaucher
Pompe

Luftveiene
Chronic Obstructive Pulmonary Disease (COPD)
Nesepolyper (CRSwNP)
Astma

Vaksiner
Respiratorisk syncytialt virus
Influensavaksiner

Transplantasjon
cGVHD (chronic Graft-versus-Host Disease)

Materiell

Diabetes: Behandling og Oppfølging
Type 1 Diabetes: Ressurser

Neurologi
Multippel sklerose

Onkologi
Hudkreft
Myelomatose

Sjelden sykdom
Fabry

Vaksiner
Influensavaksiner: Informasjon

Dermatologi
Atopisk Dermatitt

Arrangementer

Diabetes
Type 1 Diabetes

Dermatologi
Atopisk dermatitt
Prurigo nodularis

Luftveiene
Astma
Nesepolyper (CRSWNP)

Produkter
Act Hib®
Aldurazyme®
Aubagio®
Cablivi®
Cerdelga®
Cerezyme®
Dupixent®
Dupixent® Asthma
Dupixent® CRSwNP
Imovax Polio®
Fabrazyme®
Myozyme®
Nexviadyme®
Repevax®
Tetavax®
Tetravac®
Toujeo®
Typhim VI®
Zenon®

Campus

View Full Results

Myelomatose

Utdannelse

Se alt

Ressurser

Se alt

Myelomatose

Utdannelse

The Hematology Podcast - Season 5

Ressurser

IMROZ Study - Isa-VRd for patients with NDMM-TI

Phase 2 study of cemiplimab in patients with metastatic cutaneous squamous cell carcinoma: primary analysis of fixed-dosing, long-term outcome of weight-based dosing

Integrated analysis of a phase 2 study of cemiplimab in advanced cutaneous squamous cell carcinoma: extended follow-up of outcomes and quality of life analysis

Jobber du innen helsevesenet?

Myelomatose

Utdannelse

The Hematology Podcast - Season 5

Ressurser

IMROZ Study - Isa-VRd for patients with NDMM-TI

Phase 2 study of cemiplimab in patients with metastatic cutaneous squamous cell carcinoma: primary analysis of fixed-­dosing, long-­term outcome of weight-­based dosing

Integrated analysis of a phase 2 study of cemiplimab in advanced cutaneous squamous cell carcinoma: extended follow-up of outcomes and quality of life analysis

Phase 2 study of cemiplimab in patients with metastatic cutaneous squamous cell carcinoma: primary analysis of fixed-dosing, long-term outcome of weight-based dosing